xpj(中国)旗舰厅

Welcome to HitGen
CN EN

Capabilities & Services

Enabling Innovative Drug Discovery with Advanced Technologies

  • DEL for
    DEL for
  • DNA-encoded Library
    DNA-encoded Library
  • Fragment-based Drug Discovery
    FBDD/SBDD
  • Chemistry
    Chemistry
  • Bioscience
    Bioscience
  • Computational Sciences and Informatics
    Computational Sciences and Informatics
  • Structural Biology
    Structural Biology
  • Pre-clinical Studies
    Pre-clinical Studies
  • Clinical Development
    Clinical Development

Therapeutic Areas

Integrated One-stop Drug Discovery Platform   Accelerating Project with High Efficiency

  • Oncology and Immuno-oncology
    Oncology and Immuno-oncology
  • Inflammatory and Autoimmune Diseases
    Inflammatory and Autoimmune Diseases
  • Ophthalmology
    Ophthalmology
  • Infectious Diseases
    Infectious Diseases
  • Metabolic Diseases
    Metabolic Diseases
  • Cardiovascular Diseases
    Cardiovascular Diseases
HitGen Inc. is a rapidly developing biotech company
The discovery and development of novel medicines and agrochemicals
>1.2 Trillion

DNA encoded compounds

>6,000

novel drug/target complex structures for FBDD/SBDD

About Us

HitGen Inc. (SSE: 688222.SH), is a drug discovery research company with headquarters in Chengdu, China, and subsidiaries in Cambridge, UK and Houston, USA. HitGen has established leading technology platforms to enable the discovery and optimization of small molecules and nucleic acid drugs. Our key technology platforms include world-leading DNA-encoded library technology (DEL), fragment-based drug discovery and structure-based drug design technologies (FBDD/SBDD), as well as the emerging technology platforms for synthetic therapeutic oligonucleotide technology (STO), and targeted protein degradation technology (TPD). Through our diverse and flexible business models, we have built up collaboration partnership with several hundred biopharmaceutical research organizations worldwide. HitGen has multiple programmes from early discovery to clinical trial stage.


For more information, please call +86-28-85197385, +1-508-840-9646 or visit www.110962.com.

For media inquiries: media@110962.com

For investor inquiries: investors@110962.com  

For business development: bd@110962.com  


Read More

Collaboration Partners

Latest News

  • 21 February 2024

    Hox Therapeutics and Vernalis announce a drug discovery collaboration in oncology

    Hox Therapeutics Ltd (“Hox”) a private biotechnology company developing highly targeted cancer therapies and Vernalis (R&D) Ltd (“Vernalis”), a fully owned subsidiary of HitGen Inc., are pleased to announce a collaboration to identify inhibitors against an undisclosed oncology target.
    + Read More
  • 13 November 2023

    Get ready for the end-of-year sale! Discover the future of drug discovery with OpenDEL™ and save 20% off!

     

    OpenDEL™ is a self-service DNA-encoded library kit that enables users to explore DEL selection campaigns without revealing target identity and to experiment with DEL technology in your own laboratory. By following the manual and operating instructions, users can utilize OpenDEL™ to conduct affinity screening experiments against protein targets in their own laboratories


    Don't miss out on this incredible offer!

    促销-(英文)(1).jpg


    + Read More
  • 27 October 2023

    Infographic | HitGen FY2023 Q3 Report

    2023三季报长图设计(英文).jpg

    + Read More
Investors

Latest Announcements,
Financial News and Stock Information

Read More

Thanks for reading!

For more details on how we can advance your innovative drug discovery projects
验证码
By submitting your information, you acknowledge having received, read and understood our Privacy Notice as made available above.

We use cookies to provide a better web experience.
By using our site, you acknowledge our use of cookies and please read our Cookie Notice for More information